Christianne L. Roumie

Christianne L. Roumie

Auto-generated profile, based on publicly available information

Christianne L. Roumie

Geriatric Research Education and Clinical Center, and the VETWISE‐ LHS Center of Innovation Tennessee Valley Healthcare System—Veterans Health Administration Nashville Tennessee USA

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 November 2012 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
CRChristianne L. Roumie
Christianne L. Roumie
AHAdriana M. Hung
Adriana M. Hung
RGRobert A. Greevy
Robert A. Greevy
CGCarlos G. Grijalva
Carlos G. Grijalva
XLXulei Liu
Xulei Liu
MGMarie R. Griffin
Marie R. Griffin
The effects of sulfonylureas and metformin on outcomes of cardiovascular disease (CVD) in type 2 diabetes are not well-characterized. To compare the effects of sulfonylureas and metformin on CVD outcomes (acute myocardial infarction and stroke) or death. Retrospective cohort study. National Veterans Health Administration databases linked to Medicare files. Veterans who initiated metformin or sulfonylurea therapy for diabetes. Patients with chronic kidney disease or serious medical illness were excluded. Composite outcome of hospitalization for acute myocardial infarction or stroke, or death, adjusted for baseline demographic characteristics; medications; cholesterol, hemoglobin A1c, and serum creatinine levels; blood pressure; body mass index; health care utilization; and comorbid conditions. Among 253 690 patients initiating treatment (98 665 with sulfonylurea therapy and 155 025 with metformin therapy), crude rates of the composite outcome were 18.2 per 1000 person-years in sulfonylurea users and 10.4 per 1000 person-years in metformin users (adjusted incidence rate difference, 2.2 [95% CI, 1.4 to 3.0] more CVD events with sulfonylureas per 1000 person-years; adjusted hazard ratio [aHR], 1.21 [CI, 1.13 to 1.30]). Results were consistent for both glyburide (aHR, 1.26 [CI, 1.16 to 1.37]) and glipizide (aHR, 1.15 [CI, 1.06 to 1.26]) in subgroups by CVD history, age, body mass index, and albuminuria; in a propensity score–matched cohort analysis; and in sensitivity analyses. Most of the veterans in the study population were white men; data on women and minority groups were limited but reflective of the Veterans Health Administration population. Use of sulfonylureas compared with metformin for initial treatment of diabetes was associated with an increased hazard of CVD events or death. Agency for Healthcare Research and Quality and the U.S. Department of Health and Human Services.

1 August 2006 in Annals of Internal Medicine
Verified
Journal Article
Closed access
PDF file
CRChristianne L. Roumie
Christianne L. Roumie
TETom A. Elasy
Tom A. Elasy
RGRobert Greevy
Robert Greevy
MGMarie R. Griffin
Marie R. Griffin
XLXulei Liu
Xulei Liu
TSTheodore Speroff
Theodore Speroff
Inadequate blood pressure control is a persistent gap in quality care. To evaluate provider and patient interventions to improve blood pressure control. Cluster randomized, controlled trial. 2 hospital-based and 8 community-based clinics in the Veterans Affairs Tennessee Valley Healthcare System. 1341 veterans with essential hypertension cared for by 182 providers. Eligible patients had 2 or more blood pressure measurements greater than 140/90 mm Hg in a 6-month period and were taking a single antihypertensive agent. Providers who cared for eligible patients were randomly assigned to receive an e-mail with a Web-based link to the Seventh Report of the Joint National Committee on the Prevention, Detection, Evaluation and Treatment of High Blood Pressure (JNC 7) guidelines (provider education); provider education and a patient-specific hypertension computerized alert (provider education and alert); or provider education, hypertension alert, and patient education, in which patients were sent a letter advocating drug adherence, lifestyle modification, and conversations with providers (patient education). Proportion of patients with a systolic blood pressure less than 140 mm Hg at 6 months; intensification of antihypertensive medication. Mean baseline blood pressure was 157/83 mm Hg with no differences between groups (P = 0.105). Six-month follow-up data were available for 975 patients (73%). Patients of providers who were randomly assigned to the patient education group had better blood pressure control (138/75 mm Hg) than those in the provider education and alert or provider education alone groups (146/76 mm Hg and 145/78 mm Hg, respectively). More patients in the patient education group had a systolic blood pressure of 140 mm Hg or less compared with those in the provider education or provider education and alert groups (adjusted relative risk for the patient education group compared with the provider education alone group, 1.31 [95% CI, 1.06 to 1.62]; P = 0.012). Follow-up blood pressure measurements were missing for 27% of study patients. The study could not detect a mechanism by which patient education improved blood pressure control. A multifactorial intervention including patient education improved blood pressure control compared with provider education alone.

2 November 2007 in Pharmacoepidemiology and Drug Safety
Verified
Journal Article
Closed access
PDF file
CRChristianne L. Roumie
Christianne L. Roumie
EMEdward Mitchel
Edward Mitchel
PGPatricia S. Gideon
Patricia S. Gideon
CVCristina Varas‐Lorenzo
Cristina Varas‐Lorenzo
JCJordi Castellsague
Jordi Castellsague
MGMarie R. Griffin
Marie R. Griffin

11 June 2014 in JAMA
Verified
Journal Article
Open access
PDF file
CRChristianne L. Roumie
Christianne L. Roumie
RGRobert A. Greevy
Robert A. Greevy
CGCarlos G. Grijalva
Carlos G. Grijalva
AHAdriana M. Hung
Adriana M. Hung
XLXulei Liu
Xulei Liu
MGMarie R. Griffin
Marie R. Griffin
Diabetes mellitus and its complications represent an enormous health care burden and result in nearly 200 000 deaths annually. The American Diabetes Association and the European Association for the Study of Diabetes recommend that, for patients with preserved renal function, treatment begin with metformin and lifestyle changes to achieve a glycated hemoglobin (HbA1c) level of less than or equal to 7%. Often patients will require a second agent to reach this goal, but there is no consensus regarding which medication to choose: insulin, sulfonylureas, thiazolidinediones, glucagon-like peptide 1 receptor agonists, or dipeptidyl peptidase 4 inhibitors.1 Evidence to inform treatment choices after metformin monotherapy remains limited.

16 December 2010 in Journal of Behavioral Medicine
Verified
Journal Article
Closed access
PDF file
CRChristianne L. Roumie
Christianne L. Roumie
RGRobert Greevy
Robert Greevy
KWKenneth A. Wallston
Kenneth A. Wallston
TETom A. Elasy
Tom A. Elasy
LKLisa Kaltenbach
Lisa Kaltenbach
TSTheodore Speroff
Theodore Speroff

26 May 2021 in The Journal of Nutrition
Verified
Journal Article
Open access
PDF file
LFLei Fan
Lei Fan
XZXiangzhu Zhu
Xiangzhu Zhu
ARAndrea Rosanoff
Andrea Rosanoff
RCRebecca B Costello
Rebecca B Costello
CYChang Yu
Chang Yu
QDQi Dai
Qi Dai
Kidney reabsorption of magnesium (Mg) is essential for homeostasis. We developed and validated models with the kidney reabsorption-related magnesium depletion score (MDS) to predict states of magnesium deficiency and disease outcomes. MDS was validated in predicting body magnesium status among 77 adults (aged 62 ± 8 y, 51% men) at high risk of magnesium deficiency in the Personalized Prevention of Colorectal Cancer Trial (PPCCT) (registered at clinicaltrials.gov as NCT01105169) using the magnesium tolerance test (MTT). We then validated MDS for risk stratification and for associations with inflammation and mortality among >10,000 US adults (weighted: aged 48 ± 0.3 y, 47% men) in the NHANES, a nationally representative study. A proportional hazards regression model was used for associations between magnesium intake and the MDS with risks of total and cardiovascular disease (CVD) mortality. In the PPCCT, the area under the receiver operating characteristic (ROC) curve (AUC) for magnesium deficiency was 0.63 (95% CI: 0.50, 0.76) for the model incorporating the MDS with sex and age compared with 0.53 (95% CI: 0.40, 0.67) for the model with serum magnesium alone. In the NHANES, mean serum C-reactive protein significantly increased with increasing MDS (P-trend < 0.01) after adjusting for age and sex and other covariates, primarily among individuals with magnesium intake less than the Estimated Average Requirement (EAR; P-trend < 0.05). Further, we found that low magnesium intake was longitudinally associated with increased risks of total and CVD mortality only among those with magnesium deficiency predicted by MDS. MDS was associated with increased risks of total and CVD mortality in a dose-response manner only among those with magnesium intake less than the EAR. The MDS serves as a promising measure in identifying individuals with magnesium deficiency who may benefit from increased intake of magnesium to reduce risks of systemic inflammation and CVD mortality. This lays a foundation for precision-based nutritional interventions.